Literature DB >> 8618029

Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria.

N Niimi1, D M Francis, F Kermani, B F O'Donnell, M Hide, A Kobza-Black, R K Winkelmann, M W Greaves, R M Barr.   

Abstract

Previous studies identified autoantibodies against the IgE high affinity receptor alpha-chain, Fc epsilon RI alpha, in sera of selected patients with severe chronic idiopathic urticaria. We have now determined the incidence of anti-Fc epsilon RI alpha autoantibodies in a group of 163 patients. Intradermal injection of autologous serum caused skin reactions indicative of mast cell degranulation in 98 (60%) patients. Based on histamine release from IgE-sensitized and nonsensitized basophil leukocytes of healthy donors, we detected anti-Fc epsilon RI alpha autoantibodies in sera from 38 (23%) urticaria patients and evidence for anti-IgE antibodies in a further nine patients. The sera that released histamine from basophils induced histamine release (4-34%, n = 12) from mast cells in incubated skin slices. Protein-G affinity chromatography of sera demonstrated that mast cell histamine release was IgG-mediated. Preincubation of sera or the IgG fraction with a recombinant alpha-chain of Fc epsilon RI inhibited histamine release from mast cells and basophils. Further studies with the mouse anti-human Fc epsilon RI alpha antibody 29C6 showed that mast cells and basophils were similarly sensitive to IgG-mediated direct cross-linking of Fc epsilon RI, with 0.01-1.0 micrograms/ml 29C6 evoking histamine release in each case. These studies demonstrate that circulating levels of anti-Fc epsilon RI alpha autoantibodies mediate histamine release from skin mast cells in vitro and, taken together with in vivo evidence of mast cell degranulation following intradermal injection of autologous serum, support the concept that anti-Fc epsilon RI alpha autoantibodies are relevant to the pathogenesis of severe chronic urticaria in about 25% of patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618029     DOI: 10.1111/1523-1747.ep12338544

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  47 in total

1.  [Autoreactive urticaria and autoimmune urticaria].

Authors:  M Maurer; M Metz; M Magerl; F Siebenhaar; P Staubach
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

Review 2.  Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature.

Authors:  Gabriele Di Lorenzo; Maria Stefania Leto-Barone; Simona La Piana; Aurelio Seidita; Giovam Battista Rini
Journal:  Clin Exp Med       Date:  2012-05-15       Impact factor: 3.984

Review 3.  The urticarias: pathophysiology and management.

Authors:  Clive Grattan
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

4.  Treatment of chronic urticaria.

Authors:  A Kaplan
Journal:  West J Med       Date:  1997-11

5.  GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin.

Authors:  Cesar Ramirez Molina; Sidsel Falkencrone; Per S Skov; Edward Hooper-Greenhill; Mike Barker; Marion C Dickson
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

6.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Autoimmune urticaria.

Authors:  Malcolm Greaves
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

8.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

9.  Chronic autoimmune urticaria: where we stand?

Authors:  C L Goh; K T Tan
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

10.  Autologous serum skin test.

Authors:  Sudip Kumar Ghosh; Sanjay Ghosh
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.